TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors
December 17 2014 - 8:30AM
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the
appointment of Kenneth Hoberman to the Company's Board of
Directors. Mr. Hoberman is currently the Chief Operating Officer of
Stemline Therapeutics, Inc. (Nasdaq:STML), a publicly-traded
biotechnology company and was formerly the VP, Corporate and
Business Development of Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX), a publicly-traded biotechnology company.
"We are extremely pleased to be able to add Ken to our board of
directors," said Michael S. Weiss, the Company's Executive Chairman
and Interim CEO. "Ken brings to the board a strong background in
small and mid-cap biotechnology, particularly in business
development and operations, skills that will be of great value to
us as we continue to grow and seek to enhance our product pipeline
to create best-in-class combinations for B-cell malignancies. Ken
was a core member of the team that helped me build Keryx, including
identifying and developing Auryxia™, Keryx's recently approved
phosphate binder, and establishing Keryx's partnership with Japan
Tobacco/Torii. I'm very excited to have the opportunity to work
with Ken again, this time from the board level."
Kenneth Hoberman Biography
Kenneth Hoberman, 49, is currently the Chief Operating Officer
and Corporate Secretary of Stemline Therapeutics, Inc. where he was
a key member of the founding team. He was instrumental in the
company's financings from early private, including institutional,
rounds through the IPO and subsequent follow-on offerings. He has
extensive financial, accounting, investor relations, corporate
governance and business development experience including M&A,
strategic alliances and partnerships both domestic and
international. His operational expertise includes regulatory
oversight, human resources, manufacturing and clinical development.
He was previously Vice President of Corporate and Business
Development of Keryx Biopharmaceuticals, Inc., where he was
instrumental in the success of the company. He also helped secure
multiple sources of capital including over $200 million in equity
investments through public and private offerings. He also initiated
and executed a $100 million strategic alliance and originated,
negotiated and closed dozens of licensing and operational
contracts, helping to grow the company's market capitalization to
over $1 billion. He also led the team that originated, in-licensed,
and developed Auryxia™ which recently gained FDA approval. He
received a B.S.B.A. in Finance from Boston University and completed
post-baccalaureate studies at Columbia University.
ABOUT TG
THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the
acquisition, development and commercialization of novel treatments
for B-cell malignancies and autoimmune
diseases. Currently, the company is developing two
therapies targeting hematological malignancies. TG-1101
(ublituximab) is a novel, glycoengineered monoclonal antibody that
targets a specific and unique epitope on the CD20 antigen found on
mature B-lymphocytes. TG Therapeutics is also developing
TGR-1202, an orally available PI3K delta inhibitor. The delta
isoform of PI3K is strongly expressed in cells of hematopoietic
origin and is believed to be important in the proliferation and
survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in
clinical development for patients with hematologic
malignancies. The Company also has a pre-clinical program to
develop IRAK4 inhibitors, also for B-cell malignancies and
autoimmune diseases. TG Therapeutics is headquartered
in New York City.
Cautionary Statement
Some of the statements included in this press release,
particularly those, anticipating results that might be achieved at
higher doses of, and longer exposures to, TGR-1202, anticipating
future clinical trials, the timing of commencing or completing such
trials and business prospects for TG-1101 and TGR-1202 may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Among the factors that
could cause our actual results to differ materially are the
following: our ability to successfully and cost-effectively
complete pre-clinical and clinical trials for TG-1101 and TGR-1202;
the risk that early pre-clinical and clinical results that
supported our decision to move forward with TG-1101 and TGR-1202
will not be reproduced in additional patients or in future studies;
the risk that trends observed which underlie certain assumptions of
future performance of TGR-1202 will not continue, the risk that
TGR-1202 will not produce satisfactory safety and efficacy results
to warrant further development following the completion of the
current phase 1 study; the risk that the data (both safety and
efficacy) from future clinical trials will not coincide with the
data produced from prior pre-clinical and clinical trials; the risk
that trials will take longer to enroll than expected; our ability
to achieve the milestones we project over the next year; our
ability to manage our cash in line with our projections, and other
risk factors identified from time to time in our reports filed with
the Securities and Exchange Commission. Any forward-looking
statements set forth in this press release speak only as of the
date of this press release. We do not undertake to update any of
these forward-looking statements to reflect events or circumstances
that occur after the date hereof. This press release and prior
releases are available at www.tgtherapeutics.com. The
information found on our website is not incorporated by reference
into this press release and is included for reference purposes
only.
TGTX - G
CONTACT: Jenna Bosco
Director- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: ir@tgtxinc.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024